Pregnancy in a patient with tyrosinemia type 1 on treatment with nitisinone: A case report and literature review
DOI:
https://doi.org/10.52611/confluencia.2026.1877Keywords:
Pregnancy, Tyrosinemias, Inborn Errors of MetabolismAbstract
Introduction: Hereditary tyrosinemia type I is a rare inborn error of metabolism whose prognosis has improved significantly with the use of nitisinone and dietary management. Evidence regarding pregnancy in patients with hereditary tyrosinemia type I is limited and primarily based on case reports. Objective: To describe the clinical course and obstetric management of a pregnant patient with hereditary tyrosinemia type I treated with nitisinone, and to analyze the findings in relation to available literature. Methods: We report the case of a patient treated in Chile, complemented by a literature review on hereditary tyrosinemia type I, pregnancy, and nitisinone therapy. Development: A 19-year-old primigravida with hereditary tyrosinemia type I, managed with nitisinone and a restricted diet, temporarily discontinued treatment during early pregnancy due to fear of teratogenic effects; therapy was resumed following medical counseling. She developed threatened preterm labor, transient renal impairment, and fetal growth restriction, requiring multidisciplinary management and a cesarean section at 36 weeks. A newborn in good overall condition was delivered. Discussion: Continuing nitisinone promotes favorable neonatal outcomes without evidence of teratogenicity. Multidisciplinary follow-up with regular monitoring helps mitigate significant risks. Conclusion: This case reinforces the importance of metabolic control, treatment adherence, and multidisciplinary monitoring during pregnancy. Furthermore, it contributes to the limited evidence on nitisinone use during gestation and highlights the need for further research to guide clinical management in future patients.
References
1. Chinsky JM, Singh R, Ficicioglu C, van Karnebeek CDM, Grompe M, Mitchell G, et al. Diagnosis and treatment of tyrosinemia type I: a US and Canadian consensus group review and recommendations. Genet Med [Internet]. 2017 [citado el 8 de junio 2026];19(12):1380-95. Disponible en: https://doi.org/10.1038/gim.2017.101
2. Ficicioglu C. Tyrosinemia Type I. In: Adam MP, Bick S, Mirzaa GM, et al., editores. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026 [citado el 8 de junio 2026]. Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK1515/
3. Kuypers AM, Das AM, Maiorana A, Heiner-Fokkema MR, van Spronsen FJ, TT1 MetabERN Professional Collaboration Group. Overview of European Practices for Management of Tyrosinemia Type 1: Towards European Guidelines. J Inherit Metab Dis [Internet]. 2025 [citado el 8 de junio 2026];48(5):e70089. Disponible en: https://doi.org/10.1002/jimd.70089
4. van Ginkel WG, Rodenburg IL, Harding CO, Hollak CEM, Heiner-Fokkema MR, van Spronsen FJ. Long-Term Outcomes and Practical Considerations in the Pharmacological Management of Tyrosinemia Type 1. Paediatr Drugs [Internet]. 2019 [citado el 8 de junio 2026];21(6):413-26. Disponible en: https://doi.org/10.1007/s40272-019-00364-4
5. Geppert J, Stinton C, Freeman K, Fraser H, Clarke A, Johnson S, et al. Evaluation of pre-symptomatic nitisinone treatment on long-term outcomes in Tyrosinemia type 1 patients: a systematic review. Orphanet J Rare Dis [Internet]. 2017 [citado el 8 de junio 2026];12(1):154. Disponible en: https://doi.org/10.1186/s13023-017-0696-z
6. Spiekerkoetter U, Couce ML, Das AM, de Laet C, Dionisi-Vici C, Lund AM, et al. Long-term safety and outcomes in hereditary tyrosinaemia type 1 with nitisinone treatment: a 15-year non-interventional, multicentre study. Lancet Diabetes Endocrinol [Internet]. 2021 [citado el 8 de junio 2026];9(7):427-35. Disponible en: https://doi.org/10.1016/S2213-8587(21)00092-9
7. Kehar M, Sen Sarma M, Seetharaman J, Jimenez Rivera C, Chakraborty P. Decoding hepatorenal tyrosinemia type 1: Unraveling the impact of early detection, NTBC, and the role of liver transplantation. Can Liver J [Internet]. 2024 [citado el 8 de junio 2026];7(1):54-63. Disponible en: https://doi.org/10.3138/canlivj-2023-0018
8. Medina MF, Arias C, Cabello JF, De la Parra A, Valiente A, Castro G, et al. Case report: Maternal tyrosinemia type 1a under NTBC treatment with tyrosine- and phenylalanine-restricted diet in Chile. Am J Med Genet C Semin Med Genet [Internet]. 2020 [citado el 8 de junio 2026];184(4):1009-13. Disponible en: https://doi.org/10.1002/ajmg.c.31863
9. Äärelä L, Nevalainen PI, Kurppa K, Hiltunen P. First Scandinavian case of successful pregnancy during nitisinone treatment for type 1 tyrosinemia. J Pediatr Endocrinol Metab [Internet]. 2020 [citado el 8 de junio 2026];33(5):661-4. Disponible en: https://doi.org/10.1515/jpem-2019-0540
10. Zöggeler T, Ramoser G, Höller A, Jörg-Streller M, Janzen N, Ramoni A, et al. Nitisinone treatment during two pregnancies and breastfeeding in a woman with tyrosinemia type 1 - a case report. J Pediatr Endocrinol Metab [Internet]. 2022 [citado el 8 de junio 2026];35(2):259-65. Disponible en: https://doi.org/10.1515/jpem-2021-0465
11. Das AM, Ballhausen D, Haas D, Häberle J, Hagedorn T, Janson-Mutsaerts C, et al. Diagnosis, treatment, management and monitoring of patients with tyrosinaemia type 1: Consensus group recommendations from the German-speaking countries. J Inherit Metab Dis [Internet]. 2025 [citado el 8 de junio 2026];48(1):e12824. Disponible en: https://doi.org/10.1002/jimd.12824
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Revista Confluencia

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.



